Calculus Capital Limited / Stargrove Pictures Limited UK Creative Content EIS Fund

Why invest

Positives

  • Strategy: To invest in a portfolio of unquoted media companies that will generate meaningful IP.

Issues

  • Time to invest: The target time to invest of 15 months is longer than for some other EIS funds.

The Investment Manager

Positives

  • Team: One of the longest standing managers in the VCT/EIS area, Calculus has a highly experienced and stable team.

Issues

  • Past performance: While Calculus has a substantial and credible record from investing in other sectors, this is a new area for the team. However, the addition of Stargrove brings sector experience.

Nuts & bolts

  • Offer period: Closing dates are quarterly on last Fridays of October, January, April and June.
  • Diversification: The aim is to invest in at least six companies.
  • Valuation: Investors will receive valuations twice a year. Industry guidelines will be used, with two auditors examining the figures.

Specific issues

  • Fees: Mixture of direct fees and charged via the investee companies.
  • Performance fee: 20% on gains over a hurdle rate of 1.2x total capital invested.

Risks

  • Risk mitigation: Although a new sector for the Manager, Calculus will use its established investment processes and has brought in a specialist advisor in Stargrove.
  • Target return: Overall, the strategy is medium-risk relative to other EIS/VCT products, with the target capital return of 2.0x towards the top end of what we’d expect for that risk category.

DOWNLOAD THE FULL REPORT

There does not appear to be a profile here yet (if this your your plc please get in touch)
Facebook
Twitter
LinkedIn
Hardman & Co

More articles like this

Fidelity Emerging Markets

Finding long-term dividend stocks in Emerging Markets

Not all dividend-paying companies are equal, and investors face the challenge of identifying firms that can offer sustainable payouts over the long term. Emerging markets are increasingly seen as fertile ground for income and capital growth,

DirectorsTalk

Copper prices to skyrocket to $40,000 amid soaring demand

Hedge fund manager Pierre Andurand anticipates a significant increase in copper prices, expecting them to nearly quadruple to $40,000 per tonne in the next few years due to rising demand and dwindling global stockpiles. This forecast

Iron Ore futures poised for second weekly gain

Iron ore futures prices were stable on Friday but were poised for a second weekly gain, driven by sustained optimism for increased demand in China, the top consumer, fuelled by a series of property stimulus measures.

Enteq Technologies plc

Harnessing Geothermal heat for a sustainable future

Beneath the Earth’s surface lies a largely untapped source of energy: geothermal heat. Jamie Beard, the executive director of Project InnerSpace, a nonprofit dedicated to accelerating geothermal power development, explains: “The core of our Earth is

Fidelity Emerging Markets

Big-money investors shift focus to Emerging Markets

Wealthy investors are increasingly directing their funds towards emerging markets in a quest for higher returns, signalling a potential long-term change in their investment strategies, a seasoned Bank of America economist revealed to Reuters. Large global

Team Internet plc

The importance of Online Business in today’s world

In today’s business landscape, having an online presence is crucial for any active company. The pandemic has further highlighted the significance of this industry. Companies that already had online stores (e-shops) were at a significant competitive

The versatile and intriguing world of Vanadium

Vanadium, a transition metal with atomic number 23, might not be as well-known as some other elements, but it boasts a range of fascinating properties and applications. This element’s versatile uses in alloys and its role

Tern plc

Pioneering solutions for obesity and type 2 diabetes

As the quest for the ultimate solution to type 2 diabetes heats up, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) agonists have emerged as game-changing treatments, revolutionising the management of type 2 diabetes and obesity.